首页 > 最新文献

Dementia and neurocognitive disorders最新文献

英文 中文
Rapidly Progressive Behavioral Syndrome Without Spastic Paraplegia in a Patient With SPAST p.Pro26Thr Variant SPAST p.Pro26Thr变异患者无痉挛性截瘫的快速进行性行为综合征
Pub Date : 2022-04-01 DOI: 10.12779/dnd.2022.21.2.79
F. Arshad, S. Alladi, Karthik Kulanthaivelu
pulse=74/min). Neurological examination revealed echolalia, utilization behavior, prominent frontal release signs (bilateral palmo-mental reflex, glabellar tap, and snout reflex), inattention, executive
脉冲= 74 /分钟)。神经学检查显示回声、利用行为、突出的额部释放信号(双侧掌心反射、额骨轻拍和鼻反射)、注意力不集中、执行力差
{"title":"Rapidly Progressive Behavioral Syndrome Without Spastic Paraplegia in a Patient With SPAST p.Pro26Thr Variant","authors":"F. Arshad, S. Alladi, Karthik Kulanthaivelu","doi":"10.12779/dnd.2022.21.2.79","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.2.79","url":null,"abstract":"pulse=74/min). Neurological examination revealed echolalia, utilization behavior, prominent frontal release signs (bilateral palmo-mental reflex, glabellar tap, and snout reflex), inattention, executive","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73129977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Translocator Protein (18 kDa) Polymorphism (rs6971) in the Korean Population 韩国人群易位蛋白(18kda)多态性(rs6971
Pub Date : 2022-04-01 DOI: 10.12779/dnd.2022.21.2.71
Hyon Lee, Y. Noh, Woo-Ram Kim, Ha-Eun Seo, Hyeon-Mi Park
Background and Purpose The expression of the 18-kDA mitochondrial translocator protein (TSPO) in the brain is an attractive target to study neuroinflammation. However, the binding properties of TSPO ligands are reportedly dependent on genetic polymorphism of the TSPO gene (rs6971). The objective of this study is to investigate the rs6971 gene polymorphism in the Korean population. Methods We performed genetic testing on 109 subjects including patients with mild cognitive impairment, Alzheimer’s disease (AD) dementia, non-AD dementia, and cognitively unimpaired participants. Magnetic resonance imaging scans and detailed neuropsychological tests were also performed, and 29 participants underwent 18F-DPA714 PET scans. Exon 4 of the TSPO gene containing the polymorphism rs6971 (Ala or Thr at position 147) was polymerase chain reaction amplified and sequenced using the Sanger method. The identified rs6971 genotype codes (C/C, C/T, or T/T) of the TSPO protein generated high-, mixed-, or low-affinity binding phenotypes (HABs, MABs, and LABs), respectively. Results We found that 96.3% of the study subjects were HAB (105 out of 109 subjects), and 3.7% of the subjects were MAB (4 out of 109 subjects). 18F-DPA-714 PET scans showed nonspecific binding to the thalamus and brainstem, and increased tracer uptake throughout the cortex in cognitively impaired patients. The participant with the MAB polymorphism had a higher DPA714 signal throughout the cortex. Conclusions The majority of Koreans are HAB (aprox. 96%). Therefore, the polymorphism of the rs6971 gene would have a smaller impact on the availability of second-generation TSPO PET tracers.
背景与目的脑内18kda线粒体转位蛋白(TSPO)的表达是研究神经炎症的一个有吸引力的靶点。然而,据报道,TSPO配体的结合特性取决于TSPO基因的遗传多态性(rs6971)。本研究的目的是研究rs6971基因在韩国人群中的多态性。方法我们对109名受试者进行了基因检测,包括轻度认知障碍患者、阿尔茨海默病(AD)痴呆患者、非AD痴呆患者和认知未受损的参与者。还进行了磁共振成像扫描和详细的神经心理测试,29名参与者接受了18F-DPA714 PET扫描。TSPO基因外显子4包含多态性rs6971(147位Ala或Thr),采用聚合酶链反应扩增并采用Sanger法测序。所鉴定的rs6971基因型编码(C/C、C/T或T/T)分别产生高、混合或低亲和力结合表型(HABs、mab和LABs)。结果109例患者中有105例为HAB,占96.3%;109例患者中有4例为MAB,占3.7%。18F-DPA-714 PET扫描显示与丘脑和脑干的非特异性结合,认知障碍患者的整个皮层的示踪剂摄取增加。具有MAB多态性的参与者在整个皮质中具有更高的DPA714信号。结论韩国人以HAB为主。96%)。因此,rs6971基因多态性对第二代TSPO PET示踪剂可用性的影响较小。
{"title":"Translocator Protein (18 kDa) Polymorphism (rs6971) in the Korean Population","authors":"Hyon Lee, Y. Noh, Woo-Ram Kim, Ha-Eun Seo, Hyeon-Mi Park","doi":"10.12779/dnd.2022.21.2.71","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.2.71","url":null,"abstract":"Background and Purpose The expression of the 18-kDA mitochondrial translocator protein (TSPO) in the brain is an attractive target to study neuroinflammation. However, the binding properties of TSPO ligands are reportedly dependent on genetic polymorphism of the TSPO gene (rs6971). The objective of this study is to investigate the rs6971 gene polymorphism in the Korean population. Methods We performed genetic testing on 109 subjects including patients with mild cognitive impairment, Alzheimer’s disease (AD) dementia, non-AD dementia, and cognitively unimpaired participants. Magnetic resonance imaging scans and detailed neuropsychological tests were also performed, and 29 participants underwent 18F-DPA714 PET scans. Exon 4 of the TSPO gene containing the polymorphism rs6971 (Ala or Thr at position 147) was polymerase chain reaction amplified and sequenced using the Sanger method. The identified rs6971 genotype codes (C/C, C/T, or T/T) of the TSPO protein generated high-, mixed-, or low-affinity binding phenotypes (HABs, MABs, and LABs), respectively. Results We found that 96.3% of the study subjects were HAB (105 out of 109 subjects), and 3.7% of the subjects were MAB (4 out of 109 subjects). 18F-DPA-714 PET scans showed nonspecific binding to the thalamus and brainstem, and increased tracer uptake throughout the cortex in cognitively impaired patients. The participant with the MAB polymorphism had a higher DPA714 signal throughout the cortex. Conclusions The majority of Koreans are HAB (aprox. 96%). Therefore, the polymorphism of the rs6971 gene would have a smaller impact on the availability of second-generation TSPO PET tracers.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78228238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association 《2021年韩国痴呆症协会国际会议纪要:韩国痴呆症协会学术委员会报告》
Pub Date : 2022-03-14 DOI: 10.12779/dnd.2022.21.2.45
K. Park, Jae-Won Jang, Jeewon Suh, SangHak Yi, J. Bae, Jae-Sung Lim, Hyon Lee, J. Chin, Young Ho Park, Y. Hong, G. Kim
Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.
最近,aducanumab,一种β淀粉样蛋白靶向免疫疗法,已被美国食品和药物管理局批准用于治疗阿尔茨海默氏痴呆症(AD)。尽管有许多问题需要回答,但这一批准为阿尔茨海默病药物的开发提供了一个充满希望的希望,新的生物标志物,如基于血液的生物标志物和复合神经心理学测试,可以证实阿尔茨海默病早期的病理变化。阐明阿尔茨海默病的复杂性是很重要的,它已知与其他因素如血管病因和神经炎症有关。通过第2届韩国痴呆症协会(KDA)国际会议,来自世界各地的研究人员与KDA会员们就最新课题交换了意见。KDA学术委员会对讲座进行总结,以提供会议的深度和讨论。这将是一个重要的里程碑,拓宽了阿尔茨海默病的诊断、治疗、发病机制研究的最新知识,可以导致未来方向的建立。
{"title":"Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association","authors":"K. Park, Jae-Won Jang, Jeewon Suh, SangHak Yi, J. Bae, Jae-Sung Lim, Hyon Lee, J. Chin, Young Ho Park, Y. Hong, G. Kim","doi":"10.12779/dnd.2022.21.2.45","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.2.45","url":null,"abstract":"Recently, aducanumab, a beta amyloid targeted immunotherapy, has been approved by the US Food and Drug Administration for the treatment of Alzheimer’s dementia (AD). Although many questions need to be answered, this approval provides a promising hope for the development of AD drugs that could be supported by new biomarkers such as blood-based ones and composite neuropsychological tests that can confirm pathologic changes in early stages of AD. It is important to elucidate the complexity of AD which is known to be associated with other factors such as vascular etiologies and neuro-inflammation. Through the second international conference of the Korean Dementia Association (KDA), researchers from all over the world have participated in the exchange of opinions with KDA members on the most up-to-date topics. The Academic Committee of the KDA summarizes lectures to provide the depth of the conference as well as discussions. This will be an important milestone to widen the latest knowledge in the research of AD’s diagnosis, therapeutics, pathogenesis that can lead to the establishment of future directions.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80697000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study 血浆神经丝轻链在记忆临床应用的初步研究
Pub Date : 2022-03-14 DOI: 10.12779/dnd.2022.21.2.59
YongSoo Shim
Background and Purpose Neurofilament light chain (NfL) has been considered as a biomarker for neurodegenerative diseases including Alzheimer’s disease (AD). We measured plasma NfL levels in older adults with cognitive complaints and evaluated their clinical usefulness in AD. Methods Plasma levels of NfL, measured by using the single molecule array method, were acquired in a total of 113 subjects consisting of subjective cognitive decline (SCD; n=14), mild cognitive impairment (MCI; n=37), or dementia of Alzheimer type (DAT; n=62). Plasma NfL level was compared among three groups, and its association with cognitive and functional status was also analyzed. Results After adjusting for age, plasma NfL level was higher in subjects with DAT (65.98±84.96 pg/mL), compared to in subjects with SCD (16.90±2.54 pg/mL) or MCI (25.53±10.42 pg/mL, p=0.004). NfL levels were correlated with scores of the mini-mental state examination (r=−0.242, p=0.021), clinical dementia rating (CDR) (r=0.291, p=0.005), or CDR-sum of boxes (r=0.276, p=0.008). Just for participants who performed amyloid positron emission tomography (PET), the levels were different between subjects with PET (−) (n=17, 25.95±13.25 pg/mL) and PET (+) (n=16, 63.65±81.90 pg/mL, p=0.010). Additionally, plasma NfL levels were different between vascular dementia and vascular MCI, and between Parkinson’s disease- dementia and no dementia. Conclusions This pilot study shows that in subjects with DAT, plasma NfL levels increase. Plasma NfL level correlated with cognitive and functional status. Further longitudinal studies may help to apply the plasma NfL levels to AD, as a potential biomarker for the diagnosis and predicting progression.
背景与目的神经丝轻链(Neurofilament light chain, NfL)被认为是阿尔茨海默病(Alzheimer 's disease, AD)等神经退行性疾病的生物标志物。我们测量了有认知障碍的老年人血浆NfL水平,并评估了其在AD中的临床应用价值。方法采用单分子阵列法测定113例主观认知能力下降(SCD;n=14),轻度认知障碍(MCI;n=37),或阿尔茨海默氏型痴呆(DAT;n = 62)。比较三组患者血浆NfL水平,并分析其与认知和功能状态的关系。结果经年龄调整后,DAT组血浆NfL水平(65.98±84.96 pg/mL)高于SCD组(16.90±2.54 pg/mL)或MCI组(25.53±10.42 pg/mL, p=0.004)。NfL水平与迷你精神状态检查得分(r= - 0.242, p=0.021)、临床痴呆评分(r=0.291, p=0.005)或CDR- box总和(r=0.276, p=0.008)相关。仅对于进行淀粉样正电子发射断层扫描(PET)的参与者,PET (-) (n=17, 25.95±13.25 pg/mL)和PET (+) (n=16, 63.65±81.90 pg/mL, p=0.010)的水平不同。此外,血浆NfL水平在血管性痴呆和血管性MCI之间以及帕金森病-痴呆和无痴呆之间存在差异。该初步研究表明,DAT患者血浆NfL水平升高。血浆NfL水平与认知和功能状态相关。进一步的纵向研究可能有助于将血浆NfL水平应用于AD,作为诊断和预测进展的潜在生物标志物。
{"title":"Clinical Application of Plasma Neurofilament Light Chain in a Memory Clinic: A Pilot Study","authors":"YongSoo Shim","doi":"10.12779/dnd.2022.21.2.59","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.2.59","url":null,"abstract":"Background and Purpose Neurofilament light chain (NfL) has been considered as a biomarker for neurodegenerative diseases including Alzheimer’s disease (AD). We measured plasma NfL levels in older adults with cognitive complaints and evaluated their clinical usefulness in AD. Methods Plasma levels of NfL, measured by using the single molecule array method, were acquired in a total of 113 subjects consisting of subjective cognitive decline (SCD; n=14), mild cognitive impairment (MCI; n=37), or dementia of Alzheimer type (DAT; n=62). Plasma NfL level was compared among three groups, and its association with cognitive and functional status was also analyzed. Results After adjusting for age, plasma NfL level was higher in subjects with DAT (65.98±84.96 pg/mL), compared to in subjects with SCD (16.90±2.54 pg/mL) or MCI (25.53±10.42 pg/mL, p=0.004). NfL levels were correlated with scores of the mini-mental state examination (r=−0.242, p=0.021), clinical dementia rating (CDR) (r=0.291, p=0.005), or CDR-sum of boxes (r=0.276, p=0.008). Just for participants who performed amyloid positron emission tomography (PET), the levels were different between subjects with PET (−) (n=17, 25.95±13.25 pg/mL) and PET (+) (n=16, 63.65±81.90 pg/mL, p=0.010). Additionally, plasma NfL levels were different between vascular dementia and vascular MCI, and between Parkinson’s disease- dementia and no dementia. Conclusions This pilot study shows that in subjects with DAT, plasma NfL levels increase. Plasma NfL level correlated with cognitive and functional status. Further longitudinal studies may help to apply the plasma NfL levels to AD, as a potential biomarker for the diagnosis and predicting progression.","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82332126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Exploring Factors Associated With Successful Nonpharmacological Interventions for People With Dementia. 探索与痴呆患者成功非药物干预相关的因素。
Pub Date : 2022-01-01 Epub Date: 2021-12-29 DOI: 10.12779/dnd.2022.21.1.1
HyounKyoung Grace Park, Suzanne E Perumean-Chaney, Alfred A Bartolucci

Background and purpose: We investigated existing nonpharmacological programs for people with dementia (PWD) to explore critical factors related to the effectiveness of these types of programs.

Methods: We conducted a qualitative systematic literature review to identify nonpharmacological intervention programs developed for PWD and reviewed 36 randomized controlled trials. Among several outcomes reported in each study, we focused on the most common outcomes including quality of life (QoL), neuropsychiatric symptoms, depression, agitation, and cognition for further review.

Results: Several factors were identified that might affect the outcomes of nonpharmacological interventions for PWD including study design, characteristics of the intervention, maintaining research participants, heterogeneity issues, and implementation fidelity. About half of studies in this review reported positive program effects on their targeted outcomes such as Well-being and Health for PWD on improving quality of life, neuropsychiatric symptoms and agitation; cognitive stimulation therapy on QoL, neuropsychiatric symptoms and cognition; and a stepwise multicomponent intervention on neuropsychiatric symptoms, depression and agitation.

Conclusions: We found some programs even with a rigorous study design did not produce expected outcomes while other programs with poor designs reported positive outcomes, which necessitates further investigation on the validity of the assessments. Factors such as individual tailored and customized interventions, promoting social interactions, ease of administration and compatibility of interventions, and developing program theory need to be considered when developing nonpharmacological intervention programs.

背景和目的:我们调查了现有的针对痴呆症患者(PWD)的非药物治疗方案,以探索与这些方案有效性相关的关键因素。方法:我们进行了一项定性的系统文献综述,以确定针对PWD开发的非药物干预方案,并回顾了36项随机对照试验。在每项研究报告的几个结局中,我们重点关注最常见的结局,包括生活质量(QoL)、神经精神症状、抑郁、躁动和认知,以供进一步回顾。结果:确定了几个可能影响PWD非药物干预结果的因素,包括研究设计、干预特征、维持研究参与者、异质性问题和实施保真度。本综述中约有一半的研究报告了项目对其目标结果的积极影响,如福祉和健康对改善生活质量、神经精神症状和躁动的影响;认知刺激疗法对生活质量、神经精神症状和认知的影响对神经精神症状,抑郁和躁动进行逐步多成分干预。结论:我们发现即使有严格的研究设计,一些项目也没有产生预期的结果,而其他设计较差的项目报告了积极的结果,这需要进一步调查评估的有效性。在制定非药物干预计划时,需要考虑诸如个人定制和定制干预措施、促进社会互动、易于管理和干预措施的兼容性以及发展计划理论等因素。
{"title":"Exploring Factors Associated With Successful Nonpharmacological Interventions for People With Dementia.","authors":"HyounKyoung Grace Park,&nbsp;Suzanne E Perumean-Chaney,&nbsp;Alfred A Bartolucci","doi":"10.12779/dnd.2022.21.1.1","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.1.1","url":null,"abstract":"<p><strong>Background and purpose: </strong>We investigated existing nonpharmacological programs for people with dementia (PWD) to explore critical factors related to the effectiveness of these types of programs.</p><p><strong>Methods: </strong>We conducted a qualitative systematic literature review to identify nonpharmacological intervention programs developed for PWD and reviewed 36 randomized controlled trials. Among several outcomes reported in each study, we focused on the most common outcomes including quality of life (QoL), neuropsychiatric symptoms, depression, agitation, and cognition for further review.</p><p><strong>Results: </strong>Several factors were identified that might affect the outcomes of nonpharmacological interventions for PWD including study design, characteristics of the intervention, maintaining research participants, heterogeneity issues, and implementation fidelity. About half of studies in this review reported positive program effects on their targeted outcomes such as Well-being and Health for PWD on improving quality of life, neuropsychiatric symptoms and agitation; cognitive stimulation therapy on QoL, neuropsychiatric symptoms and cognition; and a stepwise multicomponent intervention on neuropsychiatric symptoms, depression and agitation.</p><p><strong>Conclusions: </strong>We found some programs even with a rigorous study design did not produce expected outcomes while other programs with poor designs reported positive outcomes, which necessitates further investigation on the validity of the assessments. Factors such as individual tailored and customized interventions, promoting social interactions, ease of administration and compatibility of interventions, and developing program theory need to be considered when developing nonpharmacological intervention programs.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3c/aa/dnd-21-1.PMC8811205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39776609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Comparison Between the Performances of Verbal and Nonverbal Fluency Tests in Discriminating Between Mild Cognitive Impairments and Alzheimer's Disease Patients and Their Brain Morphological Correlates. 言语和非言语流畅性测试在轻度认知障碍和阿尔茨海默病患者鉴别中的表现及其脑形态学相关性的比较
Pub Date : 2022-01-01 DOI: 10.12779/dnd.2022.21.1.17
Seyul Kwak, Seong A Shin, Hyunwoong Ko, Hairin Kim, Dae Jong Oh, Jung Hae Youn, Jun-Young Lee, Yu Kyeong Kim

Background and purpose: Verbal and nonverbal fluency tests are the conventional methods for examining executive function in the elderly population. However, differences in impairments result in fluency tests in patients with mild cognitive impairments (MCIs) and Alzheimer's disease (AD) and in neural correlates underlying the tests still necessitate concrete evidence.

Methods: We compared the test performances in 27 normal controls, 28 patients with MCI, and 20 with AD, and investigated morphological changes in association with the test performances using structural magnetic imaging.

Results: Patients with AD performed poorly across all the fluency tests, and a receiver operating characteristics curve analysis revealed that only category fluency test discriminated all the 3 groups. Association, category, and design fluency tests involved temporal and frontal regions, while letter fluency involved the cerebellum and caudate.

Conclusions: Category fluency is a reliable measure for screening patients with AD and MCI, and this efficacy might be related to morphological correlates that underlie semantic and executive processing.

背景和目的:语言和非语言流畅性测试是检测老年人执行功能的常规方法。然而,在轻度认知障碍(MCIs)和阿尔茨海默病(AD)患者的流畅性测试中,损伤导致的差异以及测试背后的神经相关性仍然需要具体的证据。方法:我们比较了27例正常人、28例轻度认知障碍患者和20例AD患者的测试性能,并利用结构磁成像研究了形态学变化与测试性能的关系。结果:AD患者在所有流畅性测试中的表现都很差,接受者工作特征曲线分析显示,只有类别流畅性测试能区分所有3组。联想、分类和设计流畅性测试涉及颞叶和额叶区域,而字母流畅性测试涉及小脑和尾状核。结论:类别流畅性是筛查AD和MCI患者的可靠指标,这种功效可能与语义和执行加工背后的形态学相关。
{"title":"A Comparison Between the Performances of Verbal and Nonverbal Fluency Tests in Discriminating Between Mild Cognitive Impairments and Alzheimer's Disease Patients and Their Brain Morphological Correlates.","authors":"Seyul Kwak,&nbsp;Seong A Shin,&nbsp;Hyunwoong Ko,&nbsp;Hairin Kim,&nbsp;Dae Jong Oh,&nbsp;Jung Hae Youn,&nbsp;Jun-Young Lee,&nbsp;Yu Kyeong Kim","doi":"10.12779/dnd.2022.21.1.17","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.1.17","url":null,"abstract":"<p><strong>Background and purpose: </strong>Verbal and nonverbal fluency tests are the conventional methods for examining executive function in the elderly population. However, differences in impairments result in fluency tests in patients with mild cognitive impairments (MCIs) and Alzheimer's disease (AD) and in neural correlates underlying the tests still necessitate concrete evidence.</p><p><strong>Methods: </strong>We compared the test performances in 27 normal controls, 28 patients with MCI, and 20 with AD, and investigated morphological changes in association with the test performances using structural magnetic imaging.</p><p><strong>Results: </strong>Patients with AD performed poorly across all the fluency tests, and a receiver operating characteristics curve analysis revealed that only category fluency test discriminated all the 3 groups. Association, category, and design fluency tests involved temporal and frontal regions, while letter fluency involved the cerebellum and caudate.</p><p><strong>Conclusions: </strong>Category fluency is a reliable measure for screening patients with AD and MCI, and this efficacy might be related to morphological correlates that underlie semantic and executive processing.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/b6/dnd-21-17.PMC8811206.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9506135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Association Between Body Mass Index and Cognitive Function in Mild Cognitive Impairment Regardless of APOE ε4 Status. 与APOE ε4状态无关的轻度认知障碍患者体重指数与认知功能的关系
Pub Date : 2022-01-01 Epub Date: 2022-01-12 DOI: 10.12779/dnd.2022.21.1.30
Ye Sol Mun, Hee Kyung Park, Jihee Kim, Jiyoung Yeom, Geon Ha Kim, Min Young Chun, Hye Ah Lee, Soo Jin Yoon, Kyung Won Park, Eun-Joo Kim, Bora Yoon, Jae-Won Jang, Jin Yong Hong, Seong Hye Choi, Jee Hyang Jeong

Background and purpose: In this study we aimed to find the association between neuropsychological performance and body mass index (BMI) in patients with mild cognitive impairment (MCI). In addition, we investigated the effects of the apolipoprotein E (APOE) genotype in the relationship between the BMI and cognition in MCI.

Methods: We enrolled a cohort of 3,038 subjects with MCI aged 65-90 from the Clinical Research Center for Dementia of South Korea and a dementia cohort of the Ewha Womans University Mokdong Hospital. MCI patients were classified into three subgroups according to the Asian standard of BMI. We compared cognitive performances between groups by one-way analysis of variance. To investigate the effects of the APOE genotype, we used multivariate linear regression models after adjusting for possible confounders.

Results: Even though normal BMI groups were younger, had more females, and had less comorbidities, the higher BMI groups had better cognitive functions. Among subjects with APOE ε4 carriers, there was a positive relationship between the BMI and the memory task alone.

Conclusions: Our findings suggested that higher BMI in patients with MCI were associated with better cognitive performance. The effects of the APOE ε4 genotype in the associations between BMI and cognition were distinguishing. Therefore, according to physical status, APOE ε4 genotype-specific strategies in the assessments and treatments may be necessary in elderly patients with MCI.

背景与目的:本研究旨在探讨轻度认知障碍(MCI)患者的神经心理表现与身体质量指数(BMI)之间的关系。此外,我们还研究了载脂蛋白E (APOE)基因型在MCI患者BMI和认知之间的关系中的作用。方法:我们从韩国痴呆临床研究中心和梨花女子大学木洞医院的痴呆队列中招募了3038名年龄在65-90岁之间的MCI患者。根据亚洲BMI标准将MCI患者分为三个亚组。我们通过单因素方差分析比较两组之间的认知表现。为了研究APOE基因型的影响,我们在调整了可能的混杂因素后使用了多变量线性回归模型。结果:尽管正常BMI组更年轻,女性更多,合并症更少,但高BMI组的认知功能更好。APOE ε4携带者的BMI与单纯记忆任务呈正相关。结论:我们的研究结果表明,轻度认知损伤患者的高BMI与更好的认知表现相关。APOE ε4基因型在BMI与认知关系中的作用具有显著性。因此,在老年轻度认知损伤患者的评估和治疗中,可能需要根据患者的身体状况,采用APOE ε4基因型特异性策略。
{"title":"Association Between Body Mass Index and Cognitive Function in Mild Cognitive Impairment Regardless of APOE ε4 Status.","authors":"Ye Sol Mun,&nbsp;Hee Kyung Park,&nbsp;Jihee Kim,&nbsp;Jiyoung Yeom,&nbsp;Geon Ha Kim,&nbsp;Min Young Chun,&nbsp;Hye Ah Lee,&nbsp;Soo Jin Yoon,&nbsp;Kyung Won Park,&nbsp;Eun-Joo Kim,&nbsp;Bora Yoon,&nbsp;Jae-Won Jang,&nbsp;Jin Yong Hong,&nbsp;Seong Hye Choi,&nbsp;Jee Hyang Jeong","doi":"10.12779/dnd.2022.21.1.30","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.1.30","url":null,"abstract":"<p><strong>Background and purpose: </strong>In this study we aimed to find the association between neuropsychological performance and body mass index (BMI) in patients with mild cognitive impairment (MCI). In addition, we investigated the effects of the apolipoprotein E (APOE) genotype in the relationship between the BMI and cognition in MCI.</p><p><strong>Methods: </strong>We enrolled a cohort of 3,038 subjects with MCI aged 65-90 from the Clinical Research Center for Dementia of South Korea and a dementia cohort of the Ewha Womans University Mokdong Hospital. MCI patients were classified into three subgroups according to the Asian standard of BMI. We compared cognitive performances between groups by one-way analysis of variance. To investigate the effects of the APOE genotype, we used multivariate linear regression models after adjusting for possible confounders.</p><p><strong>Results: </strong>Even though normal BMI groups were younger, had more females, and had less comorbidities, the higher BMI groups had better cognitive functions. Among subjects with APOE ε4 carriers, there was a positive relationship between the BMI and the memory task alone.</p><p><strong>Conclusions: </strong>Our findings suggested that higher BMI in patients with MCI were associated with better cognitive performance. The effects of the APOE ε4 genotype in the associations between BMI and cognition were distinguishing. Therefore, according to physical status, APOE ε4 genotype-specific strategies in the assessments and treatments may be necessary in elderly patients with MCI.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/45/dnd-21-30.PMC8811203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39776610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Clinical Practice Guideline for Dementia (Diagnosis and Evaluation): 2021 Revised Edition. 痴呆临床实践指南(诊断和评估):2021修订版。
Pub Date : 2022-01-01 Epub Date: 2022-01-21 DOI: 10.12779/dnd.2022.21.1.42
Jin San Lee, Geon Ha Kim, Hee-Jin Kim, Hee Jin Kim, Seunghee Na, Kee Hyung Park, Young Ho Park, Jeewon Suh, Joon Hyun Shin, Seong-Il Oh, Bora Yoon, Hak Young Rhee, Jae-Sung Lim, Jae-Won Jang, Juhee Chin, Yun Jeong Hong, YongSoo Shim
{"title":"Clinical Practice Guideline for Dementia (Diagnosis and Evaluation): 2021 Revised Edition.","authors":"Jin San Lee,&nbsp;Geon Ha Kim,&nbsp;Hee-Jin Kim,&nbsp;Hee Jin Kim,&nbsp;Seunghee Na,&nbsp;Kee Hyung Park,&nbsp;Young Ho Park,&nbsp;Jeewon Suh,&nbsp;Joon Hyun Shin,&nbsp;Seong-Il Oh,&nbsp;Bora Yoon,&nbsp;Hak Young Rhee,&nbsp;Jae-Sung Lim,&nbsp;Jae-Won Jang,&nbsp;Juhee Chin,&nbsp;Yun Jeong Hong,&nbsp;YongSoo Shim","doi":"10.12779/dnd.2022.21.1.42","DOIUrl":"https://doi.org/10.12779/dnd.2022.21.1.42","url":null,"abstract":"","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/ec/dnd-21-42.PMC8811204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39776611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Amyloid Burden in Alzheimer's Disease Patients Is Associated with Alterations in Circadian Rhythm. 阿尔茨海默病患者的淀粉样蛋白负担与昼夜节律改变有关
Pub Date : 2021-10-01 Epub Date: 2021-10-31 DOI: 10.12779/dnd.2021.20.4.99
Jubin Kang, Hyung Jin Choi, Gary D Isaacs, Wonjae Sung, Hee-Jin Kim

Background and purpose: In this study we evaluated the relationship between amyloid-beta (Aβ) deposition and 3 aspects of sleep quality in a group of clinically diagnosed Alzheimer's disease (AD) patients.

Methods: We used self-report questionnaires to assess the quality of sleep using 3 previously established surveys: the Glasgow Sleep Effort Scale (GSES), the Pittsburgh Sleep Quality Index (PSQI), and the Morningness-Eveningness Questionnaire (MEQ). These questionnaires focused on the sleep effort, sleep efficiency, and circadian rhythm patterns of each participant. Also, we evaluated the regional distribution of Aβ in the brain by amyloid positron emission tomography-computed tomography (PET-CT) standardized uptake value ratios (SUVRs) in healthy normal (HN), mild cognitive impairment (MCI), and AD dementia groups. The MCI and AD dementia groups were combined to form the group with cognitive impairment due to AD (CIAD).

Results: GSES and MEQ scores differed significantly between the HN, MCI, and AD dementia groups (p<0.037), whereas PSQI scores were similar across the groups (p=0.129). GSES and MEQ scores also differed between the HN and CIAD groups (p<0.018). Circadian rhythm scores positively correlated with amyloid PET-CT SUVR in posterior cingulate cortices (p<0.049).

Conclusions: Sleep effort and abnormal shifts in circadian rhythm were more significant in the CIAD group than in the HN group. At the same time, HN subjects had minimal sleep disturbance, irrespective of clinical status. Thus, alterations in circadian rhythm may be indicative of neurodegeneration due to Aβ deposition.

背景与目的:在本研究中,我们评估了一组临床诊断为阿尔茨海默病(AD)的患者中β淀粉样蛋白(a β)沉积与睡眠质量3个方面的关系。方法:采用自我报告问卷的方式,采用格拉斯哥睡眠努力量表(GSES)、匹兹堡睡眠质量指数(PSQI)和早晚性问卷(MEQ) 3项已建立的调查来评估睡眠质量。这些问卷主要关注每个参与者的睡眠时间、睡眠效率和昼夜节律模式。此外,我们通过淀粉样蛋白正电子发射断层扫描-计算机断层扫描(PET-CT)标准摄取值比(SUVRs)评估了健康正常(HN)、轻度认知障碍(MCI)和AD痴呆组Aβ在大脑中的区域分布。将MCI组和AD痴呆组合并为AD认知障碍组(CIAD)。结果:GSES和MEQ评分在HN、MCI和AD痴呆组之间差异有统计学意义(pp=0.129)。GSES和MEQ评分在HN组和CIAD组之间也存在差异(pp结论:CIAD组的睡眠努力和昼夜节律异常变化比HN组更显著。与此同时,无论临床状态如何,HN受试者的睡眠障碍最小。因此,昼夜节律的改变可能表明Aβ沉积引起的神经变性。
{"title":"Amyloid Burden in Alzheimer's Disease Patients Is Associated with Alterations in Circadian Rhythm.","authors":"Jubin Kang,&nbsp;Hyung Jin Choi,&nbsp;Gary D Isaacs,&nbsp;Wonjae Sung,&nbsp;Hee-Jin Kim","doi":"10.12779/dnd.2021.20.4.99","DOIUrl":"https://doi.org/10.12779/dnd.2021.20.4.99","url":null,"abstract":"<p><strong>Background and purpose: </strong>In this study we evaluated the relationship between amyloid-beta (Aβ) deposition and 3 aspects of sleep quality in a group of clinically diagnosed Alzheimer's disease (AD) patients.</p><p><strong>Methods: </strong>We used self-report questionnaires to assess the quality of sleep using 3 previously established surveys: the Glasgow Sleep Effort Scale (GSES), the Pittsburgh Sleep Quality Index (PSQI), and the Morningness-Eveningness Questionnaire (MEQ). These questionnaires focused on the sleep effort, sleep efficiency, and circadian rhythm patterns of each participant. Also, we evaluated the regional distribution of Aβ in the brain by amyloid positron emission tomography-computed tomography (PET-CT) standardized uptake value ratios (SUVRs) in healthy normal (HN), mild cognitive impairment (MCI), and AD dementia groups. The MCI and AD dementia groups were combined to form the group with cognitive impairment due to AD (CIAD).</p><p><strong>Results: </strong>GSES and MEQ scores differed significantly between the HN, MCI, and AD dementia groups (<i>p</i><0.037), whereas PSQI scores were similar across the groups (<i>p</i>=0.129). GSES and MEQ scores also differed between the HN and CIAD groups (<i>p</i><0.018). Circadian rhythm scores positively correlated with amyloid PET-CT SUVR in posterior cingulate cortices (<i>p</i><0.049).</p><p><strong>Conclusions: </strong>Sleep effort and abnormal shifts in circadian rhythm were more significant in the CIAD group than in the HN group. At the same time, HN subjects had minimal sleep disturbance, irrespective of clinical status. Thus, alterations in circadian rhythm may be indicative of neurodegeneration due to Aβ deposition.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/4f/dnd-20-99.PMC8585536.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39637940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Changes in Speech Range Profile Are Associated with Cognitive Impairment. 言语范围轮廓的改变与认知障碍有关。
Pub Date : 2021-10-01 Epub Date: 2021-10-31 DOI: 10.12779/dnd.2021.20.4.89
Alessandro De Stefano, Pamela Di Giovanni, Gautham Kulamarva, Francesca Di Fonzo, Tommaso Massaro, Agnese Contini, Francesco Dispenza, Claudio Cazzato

Background and purpose: The aim of this study was to describe the variations in the speech range profile (SRP) of patients affected by cognitive decline.

Methods: We collected the data of patients managed for suspected voice and speech disorders, and suspected cognitive impairment. Patients underwent an Ear Nose and Throat evaluation and Mini-Mental State Examination (MMSE). To obtain SRP, we asked the patients to read 18 sentences twice, at their most comfortable pitch and loudness as they would do in daily conversation, and recorded their voice on to computer software.

Results: The study included 61 patients. The relationship between the MMSE score and SRP parameters was established. Increased severity of the MMSE score resulted in a statistically significant reduction in the average values of the semitones to the phonetogram, and the medium and maximum sound pressure levels (p<0.001). The maximum predictivity of MMSE was based on the highly significant values of semitones (p<0.001) and the maximum sound pressure levels (p=0.010).

Conclusions: The differences in SRP between the various groups were analyzed. Specifically, the SRP value decreased with increasing severity of cognitive decline. SRP was useful in highlighting the relationship between all cognitive declines tested and speech.

背景与目的:本研究的目的是描述受认知衰退影响的患者的言语范围特征(SRP)的变化。方法:收集疑似语音、语言障碍和疑似认知障碍患者的资料。患者接受耳鼻喉评估和简易精神状态检查(MMSE)。为了获得SRP,我们要求患者以他们在日常对话中最舒服的音调和音量读两遍18个句子,并将他们的声音录在计算机软件上。结果:纳入61例患者。建立MMSE评分与SRP参数之间的关系。MMSE评分严重程度的增加导致音标的半音平均值以及中声压级和最大声压级的统计学显著降低(ppp=0.010)。结论:分析各组间SRP的差异。具体来说,SRP值随着认知衰退的严重程度而降低。SRP在强调所有测试的认知衰退和语言之间的关系方面是有用的。
{"title":"Changes in Speech Range Profile Are Associated with Cognitive Impairment.","authors":"Alessandro De Stefano,&nbsp;Pamela Di Giovanni,&nbsp;Gautham Kulamarva,&nbsp;Francesca Di Fonzo,&nbsp;Tommaso Massaro,&nbsp;Agnese Contini,&nbsp;Francesco Dispenza,&nbsp;Claudio Cazzato","doi":"10.12779/dnd.2021.20.4.89","DOIUrl":"https://doi.org/10.12779/dnd.2021.20.4.89","url":null,"abstract":"<p><strong>Background and purpose: </strong>The aim of this study was to describe the variations in the speech range profile (SRP) of patients affected by cognitive decline.</p><p><strong>Methods: </strong>We collected the data of patients managed for suspected voice and speech disorders, and suspected cognitive impairment. Patients underwent an Ear Nose and Throat evaluation and Mini-Mental State Examination (MMSE). To obtain SRP, we asked the patients to read 18 sentences twice, at their most comfortable pitch and loudness as they would do in daily conversation, and recorded their voice on to computer software.</p><p><strong>Results: </strong>The study included 61 patients. The relationship between the MMSE score and SRP parameters was established. Increased severity of the MMSE score resulted in a statistically significant reduction in the average values of the semitones to the phonetogram, and the medium and maximum sound pressure levels (<i>p</i><0.001). The maximum predictivity of MMSE was based on the highly significant values of semitones (<i>p</i><0.001) and the maximum sound pressure levels (<i>p</i>=0.010).</p><p><strong>Conclusions: </strong>The differences in SRP between the various groups were analyzed. Specifically, the SRP value decreased with increasing severity of cognitive decline. SRP was useful in highlighting the relationship between all cognitive declines tested and speech.</p>","PeriodicalId":72779,"journal":{"name":"Dementia and neurocognitive disorders","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/6a/dnd-20-89.PMC8585535.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39637470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Dementia and neurocognitive disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1